Hims & Hers Shows It's More Than Just GLP-1 Drugs

Hims & Hers Shows It's More Than Just GLP-1 Drugs

24/7 Wall St. Insights: Hims & Hers Health (HIMS) released first-quarter earnings after the closing bell on Monday and saw shares surge on the robust numbers. HIMS stock jumped 18% on Tuesday after revenue doubled, profit surged, and new subscribers roared higher.  Hims & Hers also signed a deal with Novo Nordisk (NVO) to sell its weight-loss drug Wegovy on the teleheath’s platform. Nvidia made early investors rich, but there is a new class …

Novo cuts forecasts as compounded GLP-1s weigh on sales

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.